[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ards-moderate-or-severe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ards-moderate-or-severe":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,70,92,123,147,178,199,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100580054","stimulation-to-activate-respiration-100580054",false,"NCT06832306","STimulation to Activate RespIration","A Clinical Study Evaluating Temporary Transvenous Diaphragm Neurostimulation in Mechanically Ventilated Patients With Acute Hypoxemic Respiratory Failure","STARI","Inclusion Criteria:\n\n1. Male or female, 18 years or older, and\n2. Able to provide informed consent or have a legally authorized representative (LAR) \u002F Substitute Decision Maker (SDM) who can provide consent, and\n3. Have acute onset of new respiratory symptoms or dysfunction within the 2 weeks before onset of need for respiratory support, and\n4. Have arterial hypoxemia defined by one of:\n\n   * PaO2:FiO2 ratio ≤300 mm Hg on PEEP ≥5 cm H2O, or\n   * In the absence of an available arterial blood gas, SpO2 ≤97% on FiO2 ≥0.5 and PEEP ≥5 cm H2O with reliable SpO2 trace for the 2 hours immediately preceding eligibility assessment (this correlates to an upper limit of SpO2:FiO2 ratio of 316%) or\n   * Are receiving pulmonary vasodilators for acute hypoxemia, or\n   * Are being ventilated in the prone position for acute hypoxemia, and\n5. Have been mechanically ventilated for AHRF in the ICU for \\\u003C96 hours at the time of enrolment, and\n6. Are expected to require invasive mechanical ventilation ≥48 hours after enrollment in the opinion of the treating clinician\n\nExclusion Criteria:\n\n1. Hypoxemia is primarily attributable to acute exacerbation of chronic obstructive pulmonary disease, status asthmaticus, cardiogenic pulmonary edema, or pulmonary embolism.\n2. Underlying chronic parenchymal lung disease that may make recovery\u002Fextubation a challenge (e.g., COPD, pulmonary fibrosis).\n3. Broncho-pleural fistula at the time of eligibility assessment.\n4. Require extracorporeal membrane oxygenation.\n5. Pre-existing neurological, neuromuscular or muscular disorder or known phrenic nerve injury that could affect the respiratory muscles.\n6. BMI \\>70 kg\u002Fm2.\n7. Contraindications to left internal jugular vein or left subclavian vein catheterization (e.g., infection at the access site, known central venous stenosis, septic thrombophlebitis, left internal jugular ECMO cannula in situ, poor target vessels).\n8. Patient expected to transition to fully palliative care within 72 hours of enrollment.\n9. Chronic severe liver disease (e.g., Child-Pugh Score ≥10)\n10. Treating clinician deems enrollment not clinically appropriate.\n11. Currently enrolled in any other study of an investigational drug or device, which may affect the outcomes of the current study.\n12. Any electrical device (implanted or external) that may be prone to interaction with or interference from the AeroNova System, including neurological pacing\u002Fstimulator devices and cardiac pacemakers and defibrillators.\n13. Known or suspected to be pregnant or lactating.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).",[27,28,29],"ARDS (Moderate or Severe)","AHRF","Mechanically Ventilated ICU Patients","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2025-05-28",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"Lungpacer Medical Inc.","INDUSTRY",7,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100635888","early-phase-1-a-single-dose-dose-escalation-clinical-trial-on-the-safety-tolerability-and-efficacy-of-lyophilized-powder-for-inhalation-of-recombinant-human-keratinocyte-growth-factor-2-rh-kgf-2-in-the-treatment-of-patients-with-acute-respiratory-distress-syndrome-100635888","NCT07558538","A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n1. Aged ≥18 years and \\\u003C80 years, male or female.\n2. Definite diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin Definition.\n3. Patients with PaO₂\u002FFiO₂ \\\u003C 200 mmHg and receiving invasive mechanical ventilation via endotracheal intubation.\n4. Diagnosis of ARDS confirmed no more than 72 hours prior to enrollment.\n5. No plan for parenthood within 1 year and agree to take effective contraceptive measures during the study period. Female participants of childbearing potential must have a negative serum pregnancy test.\n6. The subject fully understands the purpose of the study, as well as the nature, methods, and potential reactions of the investigational drug. The subject voluntarily signs the informed consent form to participate in the study and agrees to comply with the requirements of the study protocol. If the subject is unable to provide consent or has limited capacity to consent, consent must be obtained from the subject's legal guardian.\n\n   \\-\n\nExclusion Criteria:\n\n1. Use of inhaled pulmonary vasodilators (e.g., nitric oxide or prostaglandins).\n2. Current receipt or planned receipt of extracorporeal membrane oxygenation (ECMO) during the study period.\n3. Expected survival \\\u003C 3 months due to causes other than respiratory failure.\n4. Cerebrovascular or cardiovascular events within 3 months prior to study drug administration, including unstable angina, congestive heart failure, myocardial infarction within the past 12 months, hemodynamic instability, known left ventricular ejection fraction (LVEF) \\\u003C 40%, or clinically significant arrhythmia or conduction abnormality.\n5. Inability to tolerate single-use bronchoscopic imaging catheter examination, including but not limited to the following: active massive hemoptysis; severe hypertension and arrhythmia; myocardial infarction or unstable angina within 4-6 weeks prior to screening; severe cardiac dysfunction; uncorrectable bleeding tendency (platelet count \\\u003C 60 × 10⁹\u002FL), such as severe coagulation disorders, uremia, or severe pulmonary hypertension; severe superior vena cava syndrome; suspected aortic aneurysm; multiple pulmonary bullae.\n6. History of severe allergic reaction, or known allergy or hypersensitivity to any component of the investigational product.\n7. Breastfeeding or pregnant women.\n8. Participation in any drug clinical trial within 3 months prior to enrollment.\n9. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.","80 Years",{"count":51,"type":21},24,[53],"EARLY_PHASE1","This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.\n\nThe trial is designed with three dose groups (5 mg, 10 mg, and 15 mg), which will be escalated sequentially from the lowest dose group to the highest dose group. Each dose group will enroll 8 subjects, randomized in a 6:2 ratio according to the order of enrollment, to receive either the corresponding dose of rhKGF-2 (6 subjects) or serve as a blank control (2 subjects). Each subject will receive a single dose, administered once via a disposable bronchoscopic catheter.\n\nAll subjects will receive the trial intervention on top of standard ARDS treatment (see Concomitant Medications for details). Following the completion of drug administration, subjects will enter a 28-day follow-up period. Outcome measures include adverse events (AE), vital signs, laboratory parameters, oxygenation index (PFR), chest imaging changes, etc., to evaluate the safety, tolerability, and efficacy of the treatment.",[27,56],"ARDS (Acute Respiratory Distress Syndrome)",[56,58],"rh-KGF2","2026-06-09",{"date":61,"type":34},"2026-06-11",{"date":63,"type":34},"2026-05-14",{"date":65,"type":21},"2026-12-30",{"name":67,"class":68},"Shanghai Zhongshan Hospital","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100630688","transpulmonary-pressure-guided-mechanical-ventilation-strategy-in-right-ventricular-protection-in-patients-with-ards-100630688","NCT07490925","Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS","Application of Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With Acute Respiratory Distress Syndrome Caused by Pneumonia","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. ARDS caused by pneumonia (New Global Definition of ARDS)\n3. PaO2\u002FFiO2≤200mmHg\n4. Received invasive mechanical ventilation\n5. Sign the informed consent form\n\nExclusion Criteria:\n\n1. Invasive mechanical ventilation duration \\> 48 hours\n2. History of pulmonary hypertension caused by various reasons\n3. Severe arrhythmia\n4. BMI\\>30kg\u002Fm2\n5. Contraindications to inserting an esophageal catheter (including recent esophageal injury or surgery, severe coagulopathy (platelets \\\u003C 5×10⁹\u002FL or INR \\> 4)\n6. Pregnant and lactating women\n7. Lung transplant recipient\n8. High-risk factors for increased intracranial pressure (including intracranial hemorrhage, cerebral contusion, cerebral edema, intracranial space-occupying lesions, etc.)\n9. Active air leakage in the lungs (pneumothorax, mediastinal emphysema, bronchopleural fistula, air leakage from closed thoracic drainage tubes, etc.)\n10. Neuromuscular disease\n11. Already received salvage measures (iNO, ECMO, prone position, high-frequency oscillatory ventilation)\n12. Severe liver failure\n13. Participated in other ARDS-related studies within 30 days",{"count":78,"type":21},180,[24],"To verify whether the transpulmonary pressure-guided mechanical ventilation strategy can reduce right ventricular involvement, especially the incidence of acute cor pulmonale (ACP), in patients with moderate to severe ARDS induced by pneumonia compared with the currently widely used right ventricular protective mechanical ventilation strategy.",[27],"NOT_YET_RECRUITING","2026-03-22",{"date":85,"type":34},"2026-03-24",{"date":87,"type":21},"2026-04-01",{"date":89,"type":21},"2028-12-31",{"name":91,"class":68},"Beijing Chao Yang Hospital",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":69},"100606520","the-pre-vail-study-100606520","NCT07176624","The PRE-VAIL Study","The Effect of Reducing Enteral Nutrition Before Prone Positioning on Clinical Outcomes in Mechanically Ventilated ARDS Patients: A Multicenter Randomized Controlled Trial (The PRE-VAIL Study)","Inclusion Criteria:\n\n* Age ≥18 years old\n* Within 24 hours of admission to the ICU, one or more organ systems have failed (the Sequential Organ Failure Assessment (SOFA) score of any single organ system is ≥2)\n* Meet the diagnostic criteria for moderate\u002Fsevere ARDS (even after optimizing the ventilation Settings, the oxygenation index is still \\\u003C 150mmHg and PEEP is still ≥5 cm H2O)\n* It is expected to stay in the ICU for more than 48 hours\n\nExclusion Criteria:\n\n* There are contraindications for the prone position\n* There are contraindications for EN, preventing the initiation of early EN (≤48 hours)\n* Expected to die within 48 hours\n* Pregnancy",{"count":100,"type":21},259,[24],"During the prone position, there may be an increase in intragastric pressure. The investigators focus on a scientific question: Whether reducing enteral nutrition before the prone position will benefit patients with severe mechanically ventilated acute respiratory distress syndrome (ARDS).\n\nThe experimental group had the enteral nutrition dose reduced before the prone position, while the control group did not have the enteral nutrition dose reduced",[27,104,105,106],"Prone Position","Enteral Nutrition Feeding","Intensive Care Unit (ICU) Admission",[108,109,110,111,112,113],"ARDS","Mechanical ventilation","Prone position","Enteral nutrition","Gastric retention","Clinical outcome","2026-02-05",{"date":116,"type":34},"2026-02-09",{"date":118,"type":34},"2025-09-14",{"date":120,"type":21},"2028-02-20",{"name":122,"class":68},"The First Hospital of Jilin University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":69},"100618688","effect-of-inhaled-nitric-oxide-therapy-in-adults-with-moderate-to-severe-acute-respiratory-distress-syndrome-100618688","NCT07334873","Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome","Evaluation of the Efficacy of Inhaled Nitric Oxide Therapy in Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Multicenter, Prospective, Randomized Controlled Clinical Trial (ENARCT-ARDS)","ENARCT-ARDS","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients diagnosed with moderate-to-severe ARDS according to the 2023 Global (or international) criteria.\n\nExclusion Criteria:\n\n* Known allergy to iNO.\n* Congenital methemoglobinemia.\n* End-stage chronic lung disease (e.g., lung cancer, prior pneumonectomy\u002Flung transplant).\n* Shock (norepinephrine \\>0.5 μg\u002Fkg\u002Fmin or equivalent for \\>6 hours) at treatment initiation.\n* Pulmonary hypertension (PASP \\>45 mmHg by echo or mPAP ≥25 mmHg by catheterization).\n* Serum creatinine \\>2.5 mg\u002FdL (221 μmol\u002FL).\n* Major bleeding (e.g., intracranial, pulmonary) or platelet count \\\u003C20×10⁹\u002FL.\n* Expected ICU\u002Fmechanical ventilation \\\u003C24 hours.\n* Pre-enrollment ECMO therapy.\n* Any investigator-assessed unsuitability for the study.",{"count":132,"type":21},536,[24],"The goal of this clinical trial is to evaluate whether inhaled nitric oxide (iNO), added to standard care, can reduce mortality in adults with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). The main questions it aims to answer are:\n\nDoes iNO therapy reduce 28-day all-cause mortality compared to standard care alone? Does iNO therapy increase the number of ventilator-free days through day 28? If there is a comparison group: Researchers will compare the group receiving iNO plus standard care with the group receiving placebo plus standard care to see if iNO improves survival and other clinical outcomes.\n\nParticipants will:\n\nBe randomly assigned to receive either iNO or a placebo through the ventilator.\n\nReceive all other standard treatments for ARDS as per current guidelines. Be closely monitored for 28 days to track survival, time on the ventilator, and safety.",[27],[137,108],"Inhaled Nitric Oxide Therapy","2026-01-11",{"date":140,"type":34},"2026-01-13",{"date":142,"type":21},"2026-01",{"date":144,"type":21},"2027-12",{"name":146,"class":68},"Nanfang Hospital, Southern Medical University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":69},"100608609","peep-induced-effects-on-respiratory-drive-and-effort-100608609","NCT07203781","PEEP-induced Effects on Respiratory dRivE and EFfort","Unraveling PEEP-induced Effects on Respiratory dRivE and EFfort in Acute Hypoxemic Respiratory Failure: the REEF Study","REEF","Inclusion Criteria:\n\n* Age \\> 18 years\n* Acute hypoxemic respiratory failure (AHRF) with a PaO2\u002FFiO2-ratio ≤ 200\n* Patient on invasive assisted mechanical ventilation in pressure support mode exhibiting valid inspiratory efforts (occlusion pressure \\> 5 cmH2O).\n\nExclusion Criteria:\n\n* Pre-existent neuromuscular disease\n* History of chronic respiratory failure requiring long-term oxygen therapy\n* Muscle paralysis\n* Pneumothorax\n* Contra-indication to EIT monitoring (e.g. burns, pacemaker, thoracic wounds limiting electrode placement)\n* Contra-indications for EAdi or oesophageal balloon catheter placement (e.g. history of gastric bypass surgery, gastro-oesophageal junction surgery, oesophageal stricture, recent upper gastrointestinal hemorrhage or known\u002Fsuspected varices).",{"count":156,"type":21},20,[24],"Rationale:\n\nIn patients with acute hypoxemic respiratory failure (AHRF), preserving spontaneous breathing during mechanical ventilation offers physiological benefits, but also carries risks. While spontaneous breathing improves gas exchange and limits diaphragm atrophy, strong inspiratory efforts may worsen lung and diaphragm injury. Balancing these factors requires refined and tailored strategies, such as the modulation of PEEP. However, the impact of PEEP on neural respiratory drive and inspiratory effort is very heterogenous, and these two entities have only been studied separately in limited subsets of patients and healthy subjects. Additionally, it remains unclear whether the major determinant of PEEP-induced changes in respiratory drive and effort is represented by variations in diaphragm geometry, lung compliance, or by the presence of expiratory muscles recruitment, which may counteract its effect.\n\nObjective:\n\nThe primary objective is to determine the effect of PEEP on diaphragm neuromechanical efficiency (i.e. an index of neural respiratory drive and inspiratory effort) in patients with acute hypoxemic respiratory failure during invasive assisted mechanical ventilation. The secondary objective is to determine the major physiological contributors to PEEP-mediated changes in diaphragm neuromechanical efficiency.\n\nStudy design: Prospective, physiological study. Study population: Invasively mechanically ventilated adult patients admitted to the ICU.\n\nIntervention:\n\nFor each patient, six different PEEP levels (15-12-10-8-5-2 cmH2O) will be tested during a decremental PEEP trial. During each step, neural respiratory drive, inspiratory effort, expiratory muscle activity, lung inflation pattern through electrical impedance tomography, respiratory muscle geometry and function through ultrasound and surface EMG, gas exchange and hemodynamics data will be collected.\n\nMain study parameters\u002Fendpoints:\n\nThe primary outcome of the study will be the evaluation of PEEP-mediated changes in diaphragm neuromechanical efficiency (NME).",[27,160],"Acute Hypoxemic Respiratory Failure",[162,163,164,165,166,28,108,167,168],"PEEP","effort","drive","PSV","pressure support ventilation","diaphragm","NME","2025-11-14",{"date":171,"type":34},"2025-11-17",{"date":173,"type":34},"2025-09-02",{"date":175,"type":21},"2026-09",{"name":177,"class":68},"Radboud University Medical Center",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":69},"100590428","prone-positioning-in-ards-predicting-neurological-complications-via-cerebral-hemodynamics-100590428","NCT06967285","Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics","Changes in Cerebral Blood Flow Before and After Prone Position in Patients With ARDS Predict the Occurrence of Neurological Complications","PRONEBRAINAR","Inclusion Criteria:\n\n* Age≥18 years\n* Meet the diagnostic criteria for ARDS(Acute Respiratory Distress Syndrome),with PaO₂\u002FFiO₂\\\u003C150 mmHg,and requiring prone ventilation\n* Expected duration of mechanical ventilation\\>48 hours\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Presence of contraindications to prone positioning(e.g.,head and neck injuries,spinal instability,severe intracranial hypertension)\n* Severe neurological diseases(e.g.,cerebral hemorrhage,cerebral infarction,intracranial space-occupying lesions)that may affect the monitoring of cerebral hemodynamics\n* Life-threatening ARDS\n* Patients who are unable to undergo neurological assessment\n* Poor image quality or absence of images",{"count":187,"type":21},50,"OBSERVATIONAL","Prone Positioning in ARDS: Predicting Neurological Complications via Cerebral Hemodynamics",[27],"2025-05-03",{"date":193,"type":34},"2025-05-13",{"date":195,"type":34},"2025-03-19",{"date":87,"type":21},{"name":198,"class":68},"Sichuan Provincial People's Hospital",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":4},"100589773","combining-electrical-impedance-tomography-and-thoracic-ultrasound-toinvestigate-dynamic-changes-100589773","NCT06958770","Combining Electrical Impedance Tomography and Thoracic Ultrasound Toinvestigate Dynamic Changes","Combining Electrical Impedance Tomography and Thoracic Ultrasound to Investigate Dynamic Changes of Respiratory Effort, and Regional & End-expiratory Lung Volume in Mechanically Ventilated Patients.","Inclusion Criteria:\n\n* Adult \\>18 y\u002Fo.\n* Patient intubated and receiving mechanical ventilation \\> 24 hours.\n* Admitted into ICU, diagnosed as moderate or severe ARDS (ICD-10-CM: J80) according to Berlin definition.\n\nExclusion Criteria:\n\n* Presence of Implanted Electronic Devices (pacemakers, implantable cardioverter-defibrillators).\n* Pregnancy.\n* No consent\u002Finability to obtain consent and appropriate legal representative not available.",{"count":187,"type":21},"1. To evaluate the dynamic changes of lung ultrasound during electrical impedance tomography (EIT) PEEP titration and across the first week of ARDS.\n2. To asses respiratory effort by diaphragmatic function, esophageal pressure, and EIT (Pendelluft phenomenon), and hyperinflammatory biomarkers, to predict P-SILI.\n3. To develop predictive models for weaning success based on integrated EELI and thoracic ultrasound.",[27],[210,211],"Chest ultrasound","electrical impedance tomography","2025-04-27",{"date":214,"type":34},"2025-05-06",{"date":216,"type":21},"2025-05-19",{"date":89,"type":21},{"name":219,"class":68},"National Taiwan University Hospital",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":226,"targetDuration":227,"studyType":188,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":4},"100583591","role-of-elastic-power-in-acute-respiratory-distress-syndrome-100583591","NCT06878313","Role of Elastic Power in Acute Respiratory Distress Syndrome","Inclusion Criteria: Adult patients (≥18 years) with moderate-to-severe acute respiratory distress syndrome (ARDS), as defined by the Berlin criteria, were prospectively and consecutively included.\n\n\\-\n\nExclusion Criteria: Patients were excluded if they met at least one of the following criteria:\n\n* History of emphysema, asthma, or pneumothorax.\n* Severe instability at the time of the study preventing the PEEP titration maneuver, defined by at least one of the following indicators: SaO₂ ≤ 90%, shock requiring \\>0.5 γ\u002Fkg\u002Fmin of norepinephrine, complex arrhythmia, myocardial ischemia, or intracranial hypertension refractory to initial treatment.\n* Patients with do-not-resuscitate orders and pregnant women.",{"count":156,"type":21},"28 Days","Mechanical ventilation is essential for managing acute respiratory distress syndrome (ARDS), but it can also cause ventilator-induced lung injury (VILI) due to mechanical forces. VILI results from the interaction between lung structure and mechanical ventilation factors, such as tidal volume, plateau pressure, driving pressure, inspiratory flow, respiratory rate, and PEEP. Intrinsic factors like lung heterogeneity further increase the risk.\n\nElastic power (EP), a key component, is linked to repetitive alveolar stretching and disease progression.\n\nStudy Objectives:\n\nExamine the correlation between elastic power and pulmonary hyperinflation. Compare EP's sensitivity and specificity with other overdistension markers like driving pressure, plateau pressure, upper inflection point, and compliance.",[27,230],"Adult Patients",[108,232,233],"VILI","Mechanical Ventilation","2025-03-11",{"date":236,"type":34},"2025-03-14",{"date":238,"type":21},"2025-04-01",{"date":33,"type":21},{"name":241,"class":68},"Hospital El Cruce"]